- abnormal pituitary gland morphology / MGI
- abnormal hypothalamus morphology / MGI
- abnormal testis morphology / MGI
- Leydig cell hyperplasia / MGI
- seminiferous tubule degeneration / MGI
- decreased body weight / MGI
- infertility / MGI
- male infertility / MGI
- female infertility / MGI
- secondary sex reversal / MGI
- premature death / MGI
- abnormal reproductive system morphology / MGI
- no abnormal phenotype detected / MGI
- abnormal innervation / MGI
- abnormal primary sex determination / MGI
- abnormal secondary sex determination / MGI
- oligozoospermia / MGI
- small adrenal glands / MGI
- absent ovary / MGI
- abnormal testis development / MGI
- abnormal corticosterone level / MGI
- decreased testis weight / MGI
- absent adrenal gland / MGI
- agonadal / MGI
- absent testes / MGI
- retention of the adrenal gland x-zone / MGI
- decreased gonadotroph cell number / MGI
- abnormal neuron differentiation / MGI
- mortality/aging / MGI
- postnatal lethality, complete penetrance / MGI
- postnatal lethality, incomplete penetrance / MGI
- perinatal lethality, complete penetrance / MGI
- abnormal progesterone level / MGI
- abnormal testosterone level / MGI
- abnormal gonadal ridge morphology / MGI
- abnormal aldosterone level / MGI
- abnormal ventromedial hypothalamic nucleus morphology / MGI
- decreased ventromedial hypothalamic nucleus size / MGI
C57BL/6NTac-Nr5a1tm1(EGFP/cre/ERT2)Wtsi/WtsiIeg
Status | Available to order |
EMMA ID | EM:10083 |
International strain name | C57BL/6NTac-Nr5a1tm1(EGFP/cre/ERT2)Wtsi/WtsiIeg |
Alternative name | CEPD0029_1_A04 |
Strain type | |
Allele/Transgene symbol | Nr5a1tm1(EGFP/cre/ERT2)Wtsi |
Gene/Transgene symbol | Nr5a1 |
Information from provider
Provider | Wellcome Trust Sanger Institute |
Provider affiliation | Wellcome Trust Sanger Institute |
Genetic information | This mouse line originates from EUCOMM ES clone CEPD0029_1_A04. For further details on the construction of this clone see the page at the IMPC portal. Quality Control/Disclaimer: The structure of the targeted mutation is not fully verified. It is recommended that the recipient confirms the mutation structure by Southern blotting. The Cre expression pattern is expected to mirror that of the host gene, but this may not be fully described and/or may be modified in the targeted allele. Although characterisation of the Cre expression pattern is an objective of EUCOMMTools this is an ongoing process which may be incomplete. It is therefore recommended that the recipient verifies the Cre expression pattern. For the tm1(EGFP/Cre/ERT2) type allele, if the promoter-driven selection cassette is flanked with Rox sites, it may be removed using Dre recombinase. Please be aware that the strain description may be subject to change. For the most recent description please consult the information pages for the appropriate product details at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | Helmholtz Zentrum Muenchen - German Research Center for Environmental Health (GmbH), Oberschleißheim, Germany |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- 46,XX ovotesticular disorder of sex development / Orphanet_2138
- 46,XX testicular disorder of sex development / Orphanet_393
- Male infertility with azoospermia or oligozoospermia due to single gene mutation / Orphanet_399805
- 46,XY complete gonadal dysgenesis / Orphanet_242
- 46,XX gonadal dysgenesis / Orphanet_243
- 46,XY partial gonadal dysgenesis / Orphanet_251510
MGI phenotypes (gene matching)
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).